Market Place
Sourcing Support
Minghui Pharma Announces Phase I Results of MHB039A for Tumors
06 Nov 2024 //
PR NEWSWIRE
Minghui Announces Positive Results From Phase Ib/II Trial For TED
22 Oct 2024 //
PR NEWSWIRE
China-based biotech plans ph. 3 after seeing midstage eye data
22 Oct 2024 //
FIERCE BIOTECH
Minghui`s MHB088C B7-H3 ADC Phase 1/2 Data In Solid Tumors At ASCO
03 Jun 2024 //
PR NEWSWIRE
Minghui`s to present ph I/II study results of MHB088C to MST at ASCO meeting
10 May 2024 //
PHARMABIZ
Minghui To Present MHB088C Phase I/II Data At ASCO 2024
08 May 2024 //
PR NEWSWIRE
Minghui Announces First Patient Enrollment in Phase 3 Clinical Study of MH004
17 Aug 2023 //
PR NEWSWIRE
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Ph 1 Studies
20 Jun 2023 //
PR NEWSWIRE
Minghui doses first healthy volunteer in trial of TED therapy
24 May 2023 //
CLINICAL TRIALS ARENA
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A
23 May 2023 //
PR NEWSWIRE
Minghui Pharma Announces Phase 2 Clinical Trial Success of MH004 Cream
14 Apr 2023 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.